The CYP17 MSP AI (T-34C) and CYP19A1 (Trp39Arg) Variants in Polycystic Ovary Syndrome: A Case-control Study

Overview

Journal Int J Reprod Biomed

Specialty Reproductive Medicine

Date 2019 Aug 23

PMID 31435594

Citations 9

Authors

Zohreh Rahimi

Ehsan Mohammadi M Sc

Affiliations

Soon will be listed here.

Abstract

Background: Polycystic ovary syndrome (PCOS) is a common and chronic disorder of endocrine glands where genetic factors play a major role in the susceptibility to the disease. The cytochrome (CYP) 17 enzyme is essential for androgens biosynthesis. Also, the CYP19 enzyme converts the androgens to the aromatic estrogens.

Objective: We aimed to investigate the association of CYP 17 MSP AI (T-34C) and CYP 19A1 (Trp39Arg) variants with the pathogenesis of PCOS in a population from Western Iran with Kurdish ethnic background.

Materials And Methods: The present case-control study consisted of 50 patients with PCOS and 109 controls. The CYP17 T-34C and CYP19A1 (Trp39Arg) polymorphisms were identified by polymerase chain reaction-restriction fragment length polymorphism. The serum lipid and lipoprotein profile were detected by the Bionic Diagnostic Kits. Estradiol, dehydroepiandrosterone (DHEA), and sex hormone-binding globulin (SHBG) levels were measured using the chemiluminescent method.

Results: The serum levels of estradiol and SHBG in PCOS patients were lower than controls (p 0.001 and p = 0.06, respectively). However, the level of DHEA was higher (p = 0.01) in patients compared to controls. The higher frequency of CYP17 TC genotype in patients (30%) compared to controls (15.6%) was associated with 2.31-fold susceptibility to PCOS (p = 0.038). The frequency of CYP19 TC genotype was 6.4% in controls and 10% in patients (p = 0.42).

Conclusion: The present study suggests that CYP17 TC genotype could be associated with the risk of PCOS. Also, the study indicated the sex steroid hormones level alteration and the lower level of SHBG in PCOS patients compared to healthy individuals.

Citing Articles

CYP17A1 (rs74357) polymorphism and polycystic ovary syndrome risk: a systemic review and meta-analysis.

Rezgoun M, El Khour D, Bendaoud H, Chellat D Acta Biomed. 2023; 94(4):e2023167.

PMID: 37539608 PMC: 10440780. DOI: 10.23750/abm.v94i4.14229.

Polymorphism, along with Deletion of and Genes, Strongly Influences Female Infertility Risk.

Casteleiro Alves M, Almeida M, Oliani A, Breitenfeld L, Ramalhinho A Antioxidants (Basel). 2023; 12(4).

PMID: 37107315 PMC: 10135531. DOI: 10.3390/antiox12040940.

Underlying mechanisms of acupuncture therapy on polycystic ovary syndrome: Evidences from animal and clinical studies.

Ye Y, Zhou C, Hu H, Fukuzawa I, Zhang H Front Endocrinol (Lausanne). 2022; 13:1035929.

PMID: 36353235 PMC: 9637827. DOI: 10.3389/fendo.2022.1035929.

An update on polycystic ovary syndrome: A review of the current state of knowledge in diagnosis, genetic etiology, and emerging treatment options.

Islam H, Masud J, Islam Y, Haque F Womens Health (Lond). 2022; 18:17455057221117966.

PMID: 35972046 PMC: 9386861. DOI: 10.1177/17455057221117966.

The Association of CYP17A1, CYP19A1, and SHBG Gene Polymorphisms in Polycystic Ovary Syndrome Susceptibility: A Systematic Review and Meta-Analysis.

Xing C, Zhao H, Zhang J, He B Front Physiol. 2022; 13:741285.

PMID: 35615684 PMC: 9124751. DOI: 10.3389/fphys.2022.741285.

References

Mehdizadeh A, Kalantar S, Sheikhha M, Aali B, Ghanei A . Association of gene with polycystic ovarian syndrome in Iranian women. Int J Reprod Biomed. 2017; 15(8):491-496. PMC: 5653910. View

Jafari Y, Rahimi Z, Vaisi-Raygani A, Rezaei M . Interaction of eNOS polymorphism with MTHFR variants increase the risk of diabetic nephropathy and its progression in type 2 diabetes mellitus patients. Mol Cell Biochem. 2011; 353(1-2):23-34. DOI: 10.1007/s11010-011-0770-0. View

Panda P, Rane R, Ravichandran R, Singh S, Panchal H . Genetics of PCOS: A systematic bioinformatics approach to unveil the proteins responsible for PCOS. Genom Data. 2016; 8:52-60. PMC: 4832036. DOI: 10.1016/j.gdata.2016.03.008. View

Li Y, Liu F, Luo S, Hu H, Li X, Li S . Polymorphism T→C of gene CYP17 promoter and polycystic ovary syndrome risk: a meta-analysis. Gene. 2012; 495(1):16-22. DOI: 10.1016/j.gene.2011.12.048. View

Techatraisak K, Conway G, Rumsby G . Frequency of a polymorphism in the regulatory region of the 17 alpha-hydroxylase-17,20-lyase (CYP17) gene in hyperandrogenic states. Clin Endocrinol (Oxf). 1997; 46(2):131-4. DOI: 10.1046/j.1365-2265.1997.8700880.x. View

Diamanti-Kandarakis E, Bartzis M, Zapanti E, Spina G, Filandra F, Tsianateli T . Polymorphism T-->C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril. 1999; 71(3):431-5. DOI: 10.1016/s0015-0282(98)00512-3. View

Pusalkar M, Meherji P, Gokral J, Chinnaraj S, Maitra A . CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome. Fertil Steril. 2008; 92(2):653-9. DOI: 10.1016/j.fertnstert.2008.07.016. View

Goodarzi M, Dumesic D, Chazenbalk G, Azziz R . Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7(4):219-31. DOI: 10.1038/nrendo.2010.217. View

Ambrosone C, Moysich K, Furberg H, Freudenheim J, Bowman E, Ahmed S . CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res. 2003; 5(2):R45-51. PMC: 154148. DOI: 10.1186/bcr570. View

10.

Surekha D, Sailaja K, Rao D, Padma T, Raghunadharao D, Vishnupriya S . Association of CYP19 polymorphisms with breast cancer risk: A case-control study. J Nat Sci Biol Med. 2014; 5(2):250-4. PMC: 4121892. DOI: 10.4103/0976-9668.136150. View

11.

Marszalek B, Lacinski M, Babych N, Capla E, Biernacka-Lukanty J, Warenik-Szymankiewicz A . Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5'-UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2001; 15(2):123-8. DOI: 10.1080/gye.15.2.123.128. View

12.

Li L, Gu Z, Bo Q, Wang D, Yang X, Cai G . Association of CYP17A1 gene -34T/C polymorphism with polycystic ovary syndrome in Han Chinese population. Gynecol Endocrinol. 2014; 31(1):40-3. DOI: 10.3109/09513590.2014.947948. View

13.

Unsal T, Konac E, Yesilkaya E, Yilmaz A, Bideci A, Onen H . Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet. 2009; 26(4):205-16. PMC: 2682189. DOI: 10.1007/s10815-009-9308-8. View

14.

Piller R, Verla-Tebit E, Wang-Gohrke S, Linseisen J, Chang-Claude J . CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans. J Nutr. 2006; 136(6):1596-603. DOI: 10.1093/jn/136.6.1596. View

15.

Han Q, Shan Z, Hu J, Zhang N, Zhang X . Relationship between gene polymorphisms and prostate cancer risk. Asian Pac J Trop Med. 2015; 8(7):569-73. DOI: 10.1016/j.apjtm.2015.06.005. View

16.

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2003; 19(1):41-7. DOI: 10.1093/humrep/deh098. View

17.

Fenichel P, Rougier C, Hieronimus S, Chevalier N . Which origin for polycystic ovaries syndrome: Genetic, environmental or both?. Ann Endocrinol (Paris). 2017; 78(3):176-185. DOI: 10.1016/j.ando.2017.04.024. View

18.

Hirose K, Matsuo K, Toyama T, Iwata H, Hamajima N, Tajima K . The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. Cancer Epidemiol Biomarkers Prev. 2004; 13(8):1407-11. View

19.

Cirilo P, Rosa F, Moreira Ferraz M, Rainho C, Pontes A, Rogatto S . Genetic polymorphisms associated with steroids metabolism and insulin action in polycystic ovary syndrome. Gynecol Endocrinol. 2011; 28(3):190-4. DOI: 10.3109/09513590.2011.593661. View

20.

Kumar A, Naidu J, Satyanarayana U, Ramalingam K, Anitha M . Metabolic and Endocrine Characteristics of Indian Women with Polycystic Ovary Syndrome. Int J Fertil Steril. 2016; 10(1):22-8. PMC: 4845525. DOI: 10.22074/ijfs.2016.4764. View